AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN DIEGO -- Cyclooxygenase-2 inhibitors may offer chemoprotection against ovarian cancer by decreasing serum, and possibly follicular, levels of vascular endothelial growth factor, according to results of a small pilot study.
"This is a very small study, and we view it as simply hypothesis generating at this point. But our theory is that serum vascular endothelial growth factor (VEGF) levels might be decreased by COX-2 inhibitors, which in turn may lead to lower VEGF levels in the developing follicle, thus interfering with the normal ovulatory pathway, and, hopefully, decreasing the risk of ovarian cancer," Dr. Mack Barnes said during the annual meeting of the Society of Gynecologic Oncologists.
In a comparison of patients at increased risk for ovarian cancer who were scheduled ...